NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
Clinical Trials
9 trialsNCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00079092 2021-09-09
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Phase 2 Completed
NCT00006358 2018-06-26
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00412542 2012-02-28
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00039468 2011-10-27
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00521482 2007-08-28
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich
Phase 2 Unknown